Catalent Pharma Solutions and Zumutor Biologics, a developer of biosimilars, novel biobetters and new biological entities, unveiled a successful research study, combining Catalent’s proprietary GPEx technology and Zumutor’s fucose knockout platform, to create new and more efficacious antibodies. The GPEx technology platform creates stable, high-yielding mammalian cell lines for even the most difficult to express proteins. The advantages of applying GPEx technology span from early feasibility ...